Development of the next-generation intelligent medical packaging - using advanced micro electronics, Cloud-based IoT and big data technology to tackle medical non-adherence.

开发下一代智能医疗包装——利用先进的微电子、基于云的物联网和大数据技术来解决医疗不依从问题。

• 批准号: 49750
• 金额: $ 43.7万
• 依托单位: ORIGIN PACKAGING LIMITED
• 依托单位国家: 英国
• 项目类别: Study
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=49750
• 关键词: Development; next; generation; intelligent; medical

**Problem**Medical adherence is a global epidemic which needs to be addressed - from elongating recovery times and waste, to helping viruses develop resistance to drugs and the Opioid crisis - the consequences of patients not correctly taking their medication are extremely damaging and costly.The ultimate cost is loss of life; in the EU alone an estimated 200,000 (125,000 in the US) people die prematurely as a result of not following their medication regime properly.The financial costs are staggering also, globally, medical non-adherence costs healthcare providers £487bn [(Source- Healthprize)][0]. In the UK the [Adherence-Lets Take Care][1] of it campaign states non-adherence is draining a cash-strapped NHS £500m/annum. Money that could be used to hire extra staff, fund vital surgery or cover some of the costs of life-saving cancer therapies.**Origin's Solution**Origin Pharma's vision is to create "next-generation intelligent blister packs"- the concept is to wrap medication blister packaging with our Digital Wallet (created via Patented technology), the Digital Wallet will communicate with our cloud-based data platform as and when blister cavities are opened.The data will then be utilised by our Patient Engagement & Data platform to track and trace the interaction between the patient and the meds, 24/7\. This time critical information will allow HealthCare providers to engage with patients proactively to ensure medication adherence and offer many wider benefits to the industry and society(see outputs).**Project Focus**Utilising advanced micro electronics, Cloud-based IoT and big data technology, we will create a prototype TRL5 digital wallet (miniaturised/agile/scalable) that will be sealed (tamper evident) around a blister pack, transmitting real time data notifications to an industry standard AWS cloud based data platform.The prototype will then be trialed via an NHS led clinical trial to test the robustness and positive potential of the innovation; create proprietary data and demonstrate technical feasibility to the NHS/healthcare providers.**Outputs*** A TRL6 (post trial) Digital Wallet technology-modular, agile, sustainable* Independent validation by NHS* Reduction of loss of life to vulnerable patient groups* Reduction of clinical trial patient attrition from ~30% to <5% (improve time to market\> saving lives)* Reduction in financial loss of medical non-adherence - currently £487bn globally* Improved industry-wide insight into medication adherence via proprietary-data generation* Waste prevention(Environmental)- In Wales, more than 250 tons of out-of-date, surplus and redundant medicines each year* Reduce the burden on loved ones/cost of assisted adherence[0]: https://healthprize.com/blog/medication-adherence-pharmas-637-billion-opportunity/[1]: http://www.letstakecareofit.com/wp-content/uploads/2015/10/The-True-Cost-of-Medication-Non-Adherence-Report.pdf

** 问题 ** 医疗依从性是一个需要解决的全球流行病-从延长恢复时间和浪费，到帮助病毒对药物产生抗药性和阿片类药物危机-患者不正确服药的后果是极其有害和昂贵的。最终代价是生命损失;仅在欧盟，估计就有200，000人（美国为125，000人）因未正确遵循其药物治疗方案而过早死亡。财务成本也令人震惊，全球范围内，医疗不依从性使医疗保健提供者损失4870亿英镑[（Source- Healthprize）][0]。在英国，[坚持-让我们照顾][1]的运动指出，不坚持正在消耗现金短缺的NHS每年5亿英镑。这笔钱可以用来雇用额外的工作人员，资助重要的手术或支付挽救生命的癌症治疗的部分费用。Origin的解决方案 **Origin Pharma的愿景是创造“下一代智能泡罩包装”-概念是用我们的数字钱包包裹药物泡罩包装（通过专利技术创建），当泡罩腔被打开时，数字钱包将与我们基于云的数据平台进行通信。这些数据将被我们的患者参与和数据平台可全天候跟踪和追踪患者与药物之间的相互作用。这些时间关键的信息将使医疗保健提供者能够主动与患者接触，以确保药物依从性，并为行业和社会提供许多更广泛的好处（见输出）。项目聚焦 ** 利用先进的微电子技术、基于云的物联网和大数据技术，我们将创建TRL 5数字钱包原型（灵活/敏捷/可扩展），将被密封（防篡改）围绕泡罩包装，将真实的实时数据通知传输到行业标准的AWS基于云的数据平台。然后，该原型将通过NHS领导的临床试验进行试验，以测试其稳健性和积极潜力。创新;创建专有数据并向NHS/医疗保健提供者证明技术可行性。**输出 * A TRL 6（试用后）数字钱包技术-模块化、敏捷、* 减少弱势患者群体的生命损失 * 将临床试验患者流失率从约30%降至<5%（缩短上市时间\>挽救生命）* 减少医疗不依从的财务损失-目前全球为4870亿英镑 * 改善行业-通过专有数据生成对药物依从性的广泛洞察 * 废物预防（环境）-在威尔士，每年有超过250吨过期、多余和多余的药物 * 减轻亲人的负担/辅助依从性的成本[0]：https：//healthprize.com/blog/medication-adherence-pharmas-637-billion-opportunity/[1]：http://www.letstakecareofit.com/wp-content/uploads/2015/10/The-True-Cost-of-Medication-Non-Adherence-Report.pdf